Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 25;17(15):2462.
doi: 10.3390/cancers17152462.

The Utility of Immune Checkpoint Inhibition in the Management of Resectable Non-Small Cell Lung Cancer

Louis Filipiak  1 , Koosha Paydary  1 , Mary Jo Fidler  1 , Helen J Ross  1
Affiliations
Review

The Utility of Immune Checkpoint Inhibition in the Management of Resectable Non-Small Cell Lung Cancer

Louis Filipiak et al. Cancers (Basel). .

Abstract

Immune checkpoint inhibitors (ICIs) are approved in at least one line of therapy for most patients with advanced non-small cell lung cancer (NSCLC) without EGFR/ALK alterations and have improved survival for a subset of patients. Adjuvant, neoadjuvant, and perioperative therapy for resectable NSCLC carries the hope of more broadly increased cure rates for patients with resectable lung cancers. This review summarizes the current state of multimodality management, including ICIs, for resectable NSCLC. A literature search of PubMed and Scopus identified phase II and III clinical trials including ICIs in patients with resectable NSCLC. No level 1 evidence guides the clinician in choosing between the available neoadjuvant and perioperative approaches.

Keywords: Immune checkpoint inhibitor; Non-small cell lung cancer; perioperative.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. SEER . Cancer of the Lung and Bronchus—Cancer Stat Facts. SEER; Bethesda, MD, USA: 2025.
    1. Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K.H., De Wit M., et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017;377:1919–1929. - PubMed
    1. Wakelee H., Liberman M., Kato T., Tsuboi M., Lee S.H., Gao S., Chen K.N., Dooms C., Majem M., Eigendorff E., et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2023;389:491–503. - PMC - PubMed
    1. Forde P.M., Spicer J., Lu S., Provencio M., Mitsudomi T., Awad M., Felip E., Broderick S., Brahmer J., Swanson S., et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N. Engl. J. Med. 2022;386:1973–1985. - PMC - PubMed
    1. Heymach J.V., Harpole D., Mitsudomi T., Taube J., Galffy G., Hochmair M., Winder T., Zukov R., Garbaos G., Gao S., et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2023;389:1672–1684. - PubMed

LinkOut - more resources